Straumann with a clear strategy focus, shares in the dental sector comparison

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 12:49.

Straumann Holding AG (CH0012280076) is one of the globally recognized names in dental implants and orthodontics, with its primary listing on SIX Swiss Exchange in Zurich. On this Sunday the focus sits on the group's long-term positioning in the medtech and dental-care sector, where peers such as Stryker in the S&P 500 underline the broader market's exposure to medical equipment names.

Where Straumann stands today

Straumann, headquartered in Basel, reported full-year 2025 results earlier this year, confirming its role as a mid- to large-cap player in the Swiss equity landscape, although the stock is not a member of the SMI blue-chip index. The company operates in the medical equipment and dental devices segment, an area that has seen consistent growth as indicated by broader medtech coverage including firms like Stryker, which remains part of the S&P 500 Index.

While Straumann does not share the same index exposure as the largest Swiss names, it benefits from global demand for implantology and clear aligner products, positioning it as a specialist compared to diversified medtech giants. Sector commentary around medical equipment companies shows that investors are attentive to margin resilience and innovation pipelines in orthopaedics and dental care, themes that Straumann's business model is closely linked to.

Dental sector peers and positioning

Looking across the sector, Stryker Corporation in the United States is often cited as a reference player in medical equipment, with its shares trading in euros at around 291 on European platforms and membership in the S&P 500 Index, underscoring the scale of leading medtech firms. Stryker has recently communicated updates on its trauma portfolio and orthopaedic tools, which highlights the dynamic innovation environment in which Straumann competes indirectly on the dental side.

Straumann's positioning can also be benchmarked against broader medtech and regenerative medicine developments, where companies focus on specialised clinical solutions with recurring demand. Analyst coverage of sector names like Stryker includes notes from houses such as BofA, which recently discussed potential signs of a medtech slowdown, illustrating how macro themes can influence sentiment across medical device stocks, including dental-focused groups.

How Straumann makes its money

Straumann generates most of its revenue from dental implants, prosthetics and digital orthodontic solutions such as clear aligners, all targeted at professionals in dentistry and oral surgery. The company has built a portfolio that spans implant systems, biomaterials and digital workflows, enabling clinics to offer comprehensive tooth replacement and alignment therapies on a global basis.

Where the Straumann shares trade

The Straumann shares (CH0012280076) trade on SIX Swiss Exchange in Zurich, with the latest verifiable price data showing the stock quoted in Swiss francs on that venue; the exact intraday level and market capitalization should be checked against the current SIX pricing feed as of 2026-06-28, 12:49 for precise figures.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on sources deemed reliable but may change without notice; investors should consult official exchange data and company disclosures before making decisions.